Full-year 2026 production is now expected at the upper end of annual guidance of 50,000 to 60,000 GEO ...
In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary endpoint. The ...